XNAS · Healthcare · Drug Manufacturers - Specialty & Generic
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-13 | Q1 2026 | -0.08 | -0.08 | +0.00% | $16.0M | ➖ Inline | +7.13% | +18.88% | — |
| 2026-03-25 | Q4 2025 | -0.05 | -0.04 | +20.00% | $16.1M | ✅ Beat | -7.03% | -32.06% | -24.60% |
| 2025-11-12 |
| Q3 2025 |
| -0.05 |
| -0.09 |
| -80.00% |
| $17.6M |
| ❌ Miss |
| — |
| — |
| — |
| 2025-08-12 | Q2 2025 | -0.07 | -0.16 | -128.57% | $15.0M | ❌ Miss | -16.86% | -17.21% | -13.93% |
| 2025-03-26 | Q4 2024 | -0.22 | 0.08 | +136.36% | $13.6M | ✅ Beat | -3.58% | +1.63% | +21.66% |
| 2024-11-12 | Q3 2024 | -0.15 | -0.12 | +20.00% | $14.6M | ✅ Beat | -6.05% | -1.83% | -7.16% |
| 2024-08-12 | Q2 2024 | -0.14 | -0.17 | -21.43% | $14.9M | ❌ Miss | +14.22% | +8.29% | +13.51% |
| 2024-05-13 | Q1 2024 | -0.23 | -0.53 | -130.43% | $13.0M | ❌ Miss | +1.12% | -4.76% | +66.39% |
Showing last 8 quarters.